RD13-01 for Patients With r/r CD7+ T-ALL/T-LBL

Study Summary

This study is designed to explore the safety of RD13-01 for patients with CD7+ relapsed and/or refractory T cell acute lymphoblastic leukemia or lymphoblastic lymphoma. And to evaluate the efficacy and pharmacokinetics of RD13-01 in patients.

Interventions

Study Locations

Facility	City	State	Country
Hebei Yanda Ludaopei Hospital	Langfang	Hebei	China

Official Trial Information

View on ClinicalTrials.gov